Testing for a specific KRAS mutation in tumor tissue
Part of Cancer, Digestive system clinical trials.
This study tests your tumor tissue for a specific change in the KRAS gene called G12C. Finding this mutation may help guide treatment options for certain cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have given consent to be screened for a related study
- You have tumor tissue available for testing
- You have been diagnosed with a cancer that might involve the KRAS gene
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This trial is testing a combination of two targeted drugs (panitumumab and sotorasib) with a chemotherapy drug (5-fluorouracil) for people with advanced colorectal cancer that has a specific KRAS G12C mutation and who cannot receive stronger chemotherapy. It aims to see if this treatment can help control the cancer.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.